Catalent and Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.   “Paragon’s unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth. Paragon brings to Catalent a complementary capability that will fundamentally enhance our bi...